These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28436632)

  • 1. [Localization of gestational age reference table and its application in prenatal screening].
    Dou L; Yang G; Mo W
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2017 Jan; 46(1):59-65. PubMed ID: 28436632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of regional median equations of prenatal screening markers for trisomy 21 in a Chinese population.
    Xu L; Huang H; Zheng L; He D; Lin N; Wang L; Lin Y
    Medicine (Baltimore); 2018 Aug; 97(35):e12045. PubMed ID: 30170416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of prenatal screening for fetal chromosome abnormality during the first trimester pregnancy in Guangzhou].
    Xu Z; Li B; Liao C; Sun Q; Bai X; Li D
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Oct; 31(5):632-5. PubMed ID: 25297598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second trimester prenatal screening for Down's syndrome using alpha-fetoprotein and free beta hCG: a seven year review.
    Spencer K
    Br J Obstet Gynaecol; 1999 Dec; 106(12):1287-93. PubMed ID: 10609723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Participation in maternal serum screening for Down syndrome, neural tube defects, and trisomy 18 following screen-positive results in a previous pregnancy.
    Rausch DN; Lambert-Messerlian GM; Canick JA
    West J Med; 2000 Sep; 173(3):180-3. PubMed ID: 10986181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New cut-off values for screening of trisomy 21, 18 and open neural tube defects (ONTD) during the second trimester in pregnant women with advanced maternal age.
    Chen Y; Wang X; Li L; Lu S; Zhang Z
    BMC Pregnancy Childbirth; 2020 Dec; 20(1):776. PubMed ID: 33317474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prenatal maternal dried blood screening with alpha-fetoprotein and free beta-human chorionic gonadotropin for open neural tube defect and Down syndrome.
    Macri JN; Anderson RW; Krantz DA; Larsen JW; Buchanan PD
    Am J Obstet Gynecol; 1996 Feb; 174(2):566-72. PubMed ID: 8623786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triploidy identified through second-trimester serum screening.
    Huang T; Alberman E; Wald N; Summers AM
    Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down syndrome and neural tube defect screening: the value of using gestational age by ultrasonography.
    Benn PA; Borgida A; Horne D; Briganti S; Collins R; Rodis JF
    Am J Obstet Gynecol; 1997 May; 176(5):1056-61. PubMed ID: 9166168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency.
    Krantz DA; Hallahan TW; Orlandi F; Buchanan P; Larsen JW; Macri JN
    Obstet Gynecol; 2000 Aug; 96(2):207-13. PubMed ID: 10908764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple marker screening for trisomy 21, trisomy 18 and open neural tube defects in singleton pregnancies of native Japanese pregnant women.
    Onda T; Tanaka T; Yoshida K; Nakamura Y; Kudo R; Yamamoto H; Sato A; Yanagida K; Takai Y; Uemura H; Hoshi K; Fukada Y; Miyake Y; Ohnishi M; Kaneoka T; Makino Y; Murata Y; Kanzaki T; Kanzaki H; Osaki T; Aono T; Maeda K; Ogita S; Yamamasu S; Aso T; Shimizu Y; Izutsu T; Kudo T; Okai T; Sakai M; Hashimoto T; Matsuzaki N; Kitagawa M; Sago H; Grier RE; Myrick F; Shimizu Y
    J Obstet Gynaecol Res; 2000 Dec; 26(6):441-7. PubMed ID: 11152330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical screening of fetal aneuploidies and neural tube defects by "double-test" in Croatia: a 10 years' experience.
    Tislarić-Medenjak D; Kosec V; Tonković-Durisević I; Zec I; Sabolović-Rudman S; Kuna K; Herman R; Ivicević-Bakulić T; Soljacić-Vranes H; Tuckar N; Muzinić D; Butorac D; Bolanca I; Kosec A; Stipoljev F
    Coll Antropol; 2011 Sep; 35(3):957-62. PubMed ID: 22053587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal serum screening for Down's syndrome, open neural tube defects and trisomy 18.
    Akbas SH; Ozben T; Alper O; Ugur A; Yücel G; Lüleci G
    Clin Chem Lab Med; 2001 Jun; 39(6):487-90. PubMed ID: 11506458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.
    Aitken DA; Wallace EM; Crossley JA; Swanston IA; van Pareren Y; van Maarle M; Groome NP; Macri JN; Connor JM
    N Engl J Med; 1996 May; 334(19):1231-6. PubMed ID: 8606718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of maternal blood pregnancy-associated plasma protein A (PAPP-A) and free beta-subunit of human chorionic gonadotropin (β-hCG) levels for the risk assessment of fetal trisomy 18 during the first prenatal testing between 11 and 13+6 weeks of pregnancy.
    Ziolkowska K; Tobola-Wrobel K; Dydowicz P; Zurawski S; Pietryga M; Wysocka E
    Ginekol Pol; 2020; 91(12):748-754. PubMed ID: 33447994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal serum screening of Palestinian women in the West Bank.
    Husseini A; Akkawi M
    East Mediterr Health J; 2005 Jul; 11(4):824-7. PubMed ID: 16700399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal serum screening in Ontario using the triple marker test.
    Summers AM; Farrell SA; Huang T; Meier C; Wyatt PR
    J Med Screen; 2003; 10(3):107-11. PubMed ID: 14561260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on key techniques and intervention in reducing birth defects].
    Zhu BS; Su J; Lu XH; He J; Zhu S; Jiao CX; Zhang JM; Tang XH; Tao Y; Lin KP; Chen H; Li SY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Sep; 46(9):658-63. PubMed ID: 22176989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.